Introduction {#Sec1}
============

Glatiramoids are a class of drugs consisting in a group of heterogenous polypeptide mixtures comprising four amino acids: [l]{.smallcaps}-glutamic acid, [l]{.smallcaps}-alanine, [l]{.smallcaps}-lysine, and [l]{.smallcaps}-tyrosine \[[@CR1]\]. Glatiramer acetate (GA) is the forefather of this class \[[@CR1]\] and is used as a disease modifying drug (DMD) in patients with multiple sclerosis (MS) \[[@CR2]\]. It was originally conceived as a synthetic analogue of myelin basic protein, and initially (and surprisingly) tested to induce experimental autoimmune encephalomyelitis (EAE), the experimental model of MS in animals \[[@CR3]\]. After it was shown that, instead of promoting, it suppressed EAE \[[@CR4]\], this molecule was explored for its possible therapeutic effect, although its mechanism of action is still not fully known \[[@CR2]\]. GA's mechanism of action encompasses both anti-inflammatory properties (such as promoting a shift toward a Th2 pattern for reactive T cells, reducing production of inflammatory cytokines and enhancing T regulatory cells and anti-inflammatory cytokines \[[@CR5]--[@CR8]\]) as well as neuroprotective properties (such as increasing levels of neurotrophic factors, favoring axonal protection and possibly reducing glutamate-mediated neurotoxicity \[[@CR9]--[@CR11]\]). Among biological characteristics of GA, its immunogenicity needs to be highlighted for the purposes of this review: in a high proportion of patients treated with GA a low but significant titer of anti-GA antibodies (anti-GA) is produced \[[@CR12]\]. Anti-GAs do not interfere with its efficacy \[[@CR13]\].

After GA was tested in several studies over 25 years, two large randomized controlled trials have been performed testing GA in patients with MS. In the US glatiramer acetate study \[[@CR14]\], a 29% reduction of the annualized relapse rate (ARR) favoring GA over placebo was observed, and in the European--Canadian MRI study \[[@CR15]\], GA-treated patients showed a reduction of roughly 70% of gadolinium-enhancing (Gd+) lesions versus placebo. These studies ultimately led to GA approval as a DMD for MS in 2001.

Fifteen years later, GA's patent expired, leading to great interest in the development of new members of its class. Not all glatiramoids have shown favorable outcomes in the treatment of MS \[[@CR1]\]. In the present review, we will discuss the regulatory and statistical background of generic drugs for MS, and we will present preclinical and clinical evidence of Copemyl^®^, a new glatiramoid, 20 mg administered subcutaneously (sc) daily, and discuss its equivalence to former GA in terms of efficacy and safety profile. This article is therefore based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Regulation of Generic Drugs and Biosimilars and the Case of Non-Biological Complex Drugs {#Sec2}
========================================================================================

A generic medicinal product is defined as a product which has the same qualitative and quantitative composition in active substances and the same pharmaceutical form as the reference medicinal product, and whose bioequivalence with the reference medicinal product has been demonstrated by appropriate bioavailability studies \[[@CR16]\].

A biosimilar drug is a drug similar to a biological drug, i.e., according to the European Medicines Agency (EMA) definition: "A product, the active substance of which is a biological substance. A biological substance is a substance that is produced by or extracted from a biological source and that needs for its characterization and the determination of its quality a combination of physicochemical--biological testing, together with the production process and its control" \[[@CR16]\].

There are several drugs that are neither classic small molecules nor biological substances. These drugs are called non-biological complex drugs (NBCDs) and consist mainly of therapeutic proteins; for instance: liposomal drugs, iron carbohydrate drugs ("iron-sugars"), and drugs belonging to the category of glatiramoids \[[@CR17], [@CR18]\]. The regulation of biosimilars is not applicable to those products, as they are not the originator a biological substance. On the other hand, the classical paradigm for the marketing of a generic drug cannot be used for NBCDs either, mainly because of the complexity of their structure that impairs classical structure analysis and pharmacokinetic studies \[[@CR19]--[@CR21]\]; therefore, these products resist regulation of their own.

The EMA regulates the approval of NBCDs and their marketing under Article 10(3) of Directive 2001/83/EC \[[@CR16]\]. Article 10(3) does not impose the new drug and the originator to be identical, but states that for the approval of the new version, results of appropriate preclinical testing or clinical trials shall be provided. Applications for NBCDs will thus rely in part on the results of preclinical tests and clinical trials for the reference product, and in part on new data for the new version of the drug. Specifically, for new versions of GA such new data consisted in a randomized three-arm equivalence trial, including a placebo arm, a reference GA arm, and an arm treated with the new GA. Such an approach is in line with what was proposed in consensus meetings on therapeutic equivalence \[[@CR17]\] and was agreed with the EMA Committee for Medicinal Products for Human Use (CHMP) \[[@CR22]\] as further discussed. Given the current lack of specific EMA rules for the management of NBCDs registration, it should be considered---purely on practical grounds---that the EMA requires mandatory centralized procedures for the marketing authorization of biosimilar drugs. GA is not considered a biologic and therefore the EU biologics and biosimilar legislation and regulatory pathway is not applicable; in fact, GA copies were not registered through a centralized procedure.

The US Food and Drug Administration (FDA), unlike EMA regulation, does not require data from randomized trials to demonstrate sameness for complex active ingredients, such as GA, but, in addition to standards applied to evaluate all generic drug products, it requires "appropriate information" \[[@CR23]\]. That further information for GA consisted mainly of demonstration of physicochemical equivalence and equivalent biological and immunological effects in EAE and were considered sufficient to approve another version of GA in 2015 \[[@CR24]\]. Other glatiramoids purported to be generic GA are marketed in various countries for the treatment of MS patients \[[@CR15]\]. Table [1](#Tab1){ref-type="table"} summarizes all different glatiramoids developed so far.Table 1Glatiramoid class membersGlantiramoidManufacturerNotesFDA/EMA approvalMarketScientific support to regulatory approvalCopaxone^®^TEVADMD for MSFDA and EMASeveral countries worldwideOriginatorCopemyl^®^MylanDMD for MSEMASeveral countries worldwide with different commercial nameQuality, preclinical and clinical dataGlatopa^®^SandozDMD for MSFDAUSANoEscadra^®^RaffoDMD for MSNoArgentinaNoGTR polimunol^®^SynthonDMD for MSNoArgentinaNoProbioglat^®^ProbiomedDMD for MSNoMexicoNoGlatimer^®^NATCODMD for MSNoIndiaNoProtiramerTEVADevelopment halted on basis of results of long-term animal toxicity studies \[[@CR1]\]NoN/ANo

Methodology of Equivalence Trials {#Sec3}
=================================

Trials to test the clinical efficacy of generic drugs are necessarily equivalence trials, aimed at demonstrating that the drug is equivalent to the original compound. This is the first critical issue to be taken into account: a non-inferiority condition is not sufficient and the two drugs must have the same efficacy. Assessing equivalence of two drugs is generally more difficult than assessing superiority of one drug over another, and it requires larger numbers of patients. The reason for that lies in the definition of "equivalence". In an equivalence trial the null hypothesis (that we want to reject) is that the new drug has an inferior (or a superior) efficacy than the original drug, while the alternative hypothesis is that the new drug has the same efficacy as the original one \[[@CR25]\]. Therefore, the first step for designing an equivalence trial is to define what we mean for "equivalent" and this definition implies the need to set the so-called equivalence margin. The equivalence margin is the interval of differences (around zero) between the new and the original drug that we can consider clinically not relevant, so that if the difference detected in the trial lies within this interval we can declare that the two drugs are clinically equivalent. It is obvious that the equivalence margin must be narrow and in any case narrower than the interval used to declare superiority \[[@CR26]\]. If, for example, in a study in MS we define a new drug superior to the standard drug if the former reduces the relapse rate of 30% more than the latter, the equivalence margin for two drugs in MS must be narrower than 30%. We could tolerate, for example, a difference in relapse rate of 15% as a difference with no clinical relevance, so that we could decide to set the equivalence margin as \[−15%, +15%\]. The narrower the interval, the higher the likelihood that the two drugs are equivalent, but the larger the sample size needed \[[@CR25]\].

Preclinical Data {#Sec4}
================

The synthesis of Copemyl is based on the same chemistry as the synthesis published for GA, which results in the complex heterogenous mixture of random polypeptide chains ranging from 20 to 200 amino acids with an average of 60 amino acids in length. Consequently, it has been estimated that any of more than 1029 different potential polypeptide sequences could be found in GA and in Copemyl \[[@CR27]\]. The manufacturer of Copemyl has performed an extensive physicochemical and biological characterization program comparing the active substance present in Copemyl and GA, using a panel of chemical and biological assays, including primary structure evaluation, complex structure evaluation, UV spectroscopy, and capillary isoelectric focusing \[[@CR27]\].

Bioequivalence between Copemyl and GA was tested via several bioassays. Copemyl and GA were compared in a study evaluating their effect in modulating gene expression in the human monocytic THP-1 cell line \[[@CR28]\]. In this study five Copemyl batches were compared to five GA batches using the GeneChip^®^ Human GenomeU133 Plus 2.0 Array (Thermo Fisher Scientific Inc.) for analysis of genome-wide expression, evaluated by microarray after 6 h exposure of THP-1 cells in vitro to either Copemyl or GA, showing that the variability of the modulated genes of the Copemyl batches was similar to that of the GA batches (specifically, a total of 52 probe sets were significantly up- or downregulated by Copemyl and 60 by GA, compared to vehicle-treated samples. The variability of the modulated genes of the Copemyl batches was similar to that of the GA batches). Another study focused on induction and activation of glatiramer-specific T cells in EAE \[[@CR29]\]. Mice were immunized with different batches of either GA or Copemyl, and 10 days later lymphocytes were obtained from the draining lymph nodes. The isolated cells were cultured and restimulated with increasing doses of GA in vitro. GA-specific T cells respond to in vitro (re)stimulation with increased proliferation and cytokine---including interleukin-2 (IL-2)---production \[[@CR30]\]. IL-2 levels were quantified and the GA-dependent IL-2 secretion served as a parameter for bioactivity. The bioactivities ranged between 61.6% and 94.3% for Copemyl batches and between 56.3% and 94.8% for GA batches, thus confirming analogous immunomodulatory properties. Comparative toxicity studies were performed in rats \[[@CR27]\] to whom Copemyl and GA were administered subcutaneously by daily injection showing analogous local reactions and liver effects, with no difference in frequency and severity of these effects in rats treated with Copemyl and rats treated with GA.

Clinical Data {#Sec5}
=============

Copemyl was evaluated in patients with MS in two trials: the 9-month GATE trial \[[@CR31]\] and its 15-month extension \[[@CR32]\]. The GATE study is a randomized, double blind active and placebo-controlled equivalence trial conducted in 17 countries in 2011--2013 and published in 2015. Patients included were naïve to GA, had mild to moderate disability \[Expanded Disability Status Scale (EDSS) \[[@CR33]\] of 0--5.5\], and had an active disease (a relapse in the previous year, and 1--15 Gd+ lesions at the screening scan). A total of 796 patients were randomized to either Copemyl 20, GA, or placebo, with a ratio of 4.3:4.3:1. The primary endpoint was the number of Gd+ lesions during months 7--9, with an equivalence margin (EM) tailored considering results of the former GA Euro-Canadian study \[[@CR15]\], as further discussed. Equivalence required both statistically significant superiority to placebo and a 95% CI within predefined equivalence margins for the ratio of Gd+ lesions between Copemyl and GA. Most relevant baseline characteristics of the randomized patients (and comparison with the reference GA trials) are illustrated in Table [2](#Tab2){ref-type="table"}, while Fig. [1](#Fig1){ref-type="fig"} displays results of the primary endpoint. MRI of Copemyl- and GA-treated patients showed a mean number of Gd+ lesions lower than those administered placebo (ratio 0.488; 95% CI 0.365--0.651; *P* \< 0.001), confirming study sensitivity. The estimated ratio of Copemyl to GA Gd+ lesions was 1.095 (95% CI 0.883--1.360), which fell within the predefined equivalence margin; therefore, the authors concluded equivalence between Copemyl and GA. ARR, though calculated over 9 months, did not differ in the three arms \[0.31 (95% CI 0.20--0.48) for Copemyl, 0.40 (95% CI 0.26--0.62) for GA, and 0.38 (95% CI 0.22--0.66) for placebo\]. In the three groups mean EDSS score was stable, percentage of relapse-free or disease-activity-free patients did not differ, and no statistically relevant difference in new T2 MRI lesions was shown. Adverse events (AEs) were evenly reported in all arms of the study; trademark GA adverse events such as injection site reactions (ISR) and immediate post-injection reactions occurred (PIR) in the same proportion of patients assigned to GA or Copemyl; namely ISR were reported by 16.4% of the patients in the Copemyl arm and 17.4% of those in the GA arm, while PIR occurred respectively in 6.8% of the patients for Copemyl and 5% of the patients for GA.Table 2GATE trial patients baseline characteristics, compared with baseline characteristics of patients enrolled in the two pivotal trials of GACharacteristicGATE trial \[[@CR31]\]Eu/Can trial \[[@CR15]\]US trial \[[@CR14]\]Placebo (*n* = 84)GA (*n* = 357)Copemyl (*n* = 353)Placebo (*n* = 120)GA (*n* = 119)Placebo (*n* = 126)GA (*n* = 125)Mean age, years (SD)32.6 (8.7)33.8 (9)32.6 (8.6)34 (7.5)34.1 (7.4)34.3 (6.5)34.6 (6)Female sex67.9%66.7%66%76.2%70.4%Mean time from onset of symptoms to randomization, years (SD)5.7 (6)6.4 (6)5.5 (5.3)8.3 (5.5)7.9 (5.5)6.6 (5.1)7.3 (4.9)Mean number of relapses in prior 2 years (SD)1.9 (0.9)1.8 (0.9)1.9 (0.9)2.5 (1.4)2.8 (1.8)2.9 (1.1)2.9 (1.3)Patients naive to DMDs11.9%17.4%15.9%Baseline EDSS Mean (SD)2.7 (1.2)2.7 (1.2)2.6 (1.2)2.4 (1.2)2.3 (1.1)2.4 (1.3)2.8 (1.2) Median (range)2.5 (0--5.5)2.5 (0--5.5)2.5 (0--6.0)Mean number of Gd+ lesions (SD) at baseline MRI Mean (SD)2.8 (4.1)2.5 (3.9)2.5 (3.5)4.4 (7.1)4.2 (4.8) Median (range)1 (0--28)1 (0--40)1 (0--27)Number of hyperintense lesions in T2-weighted scans Mean (SD)47.6 (34.7)49.6 (31.9)51.9 (37.7) Median (range)42 (2--168)45 (0--238)45 (2--363)Volume of hyperintense lesions in T2-weighted scans (mm^3^) Mean (SD)9122 (11,842)8311 (8386)9096 (10,410) Median (range)4740 (157--59,506)5015 (0--46,594)5384 (174--84,727)Volume of hyperintense lesions in T1-weighted scans (mm^3^) Mean (SD)2091 (4329)1462 (2741)1686 (3298) Median (range)489 (0--22,829)389 (0--23,406)500 (0--27,900) Fig. 1Primary endpoint of the GATE trial \[[@CR31]\]: *left* main number of Gd+ lesions in months 7--9 in the three arms of the study and *right* predefined equivalence margins of *n*-GA versus GA.This figure is slightly modified in terms of color and with supplementary notes from \[[@CR31]\]. Copyright permission from American Medical Association, owner of the rights of the article, was obtained on June 16, 2017

Patients enrolled in the GATE study were offered the possibility to continue in a 15-month open-label extension trial, whose results have been recently published \[[@CR32]\]. Of the 796 patients of the GATE study, 728 agreed to participate in the extension and all were treated with Copemyl. Of these, 670 completed the trial (92%). For analysis purposes subjects enrolled into the extension trial were divided into three arms: patients treated with placebo in the GATE trial (pbo/Copemyl, *n* = 81), patients assigned to GA arm in the GATE trial (GA/Copemyl, *n* = 323), and patients randomized to Copemyl in the GATE trail (Copemyl/Copemyl, *n* = 324). MRI conducted at month 12, 18, and 24 from GATE trial randomization showed a similar mean number of Gd+ lesions for GA/Copemyl patients and Copemyl/Copemyl patients (0.6--0.7 in both groups), while pbo/Copemyl patients showed a higher mean number of Gd+ lesion at the 12-month scan (1.7), declining to 0.7 and 0.9 at months 18 and 24, respectively (Fig. [2](#Fig2){ref-type="fig"}).The change in the number of new T2 lesions was similar in the Copemyl/Copemyl and GA/Copemyl groups but higher in the placebo/Copemyl group. Changes in other MRI parameters (T2 lesion volume, T1 hypointense lesion volume, and brain volume) were similar in the Copemyl/Copemyl and GA/Copemyl groups and larger in the placebo/Copemyl group. In parallel to what was observed in the core trial, clinical outcomes, in particular ARR (0.21, 0.24, and 0.23 for Copemyl/Copemyl, GA/Copemyl, and placebo/Copemyl, respectively) did not differ among the three groups. The authors state that these figures are comparable to the 2-year ARR reported in recent clinical trials with GA. Injection-related AEs were similarly low in the GA/Copemyl group and Copemyl/Copemyl group (respectively 0.9% and 1.2% for injection site reactions and 0.9% and 2.2% for immediate post-injection reactions), while injection site reactions were reported in 9.9% and immediate post-injection reactions in 1.2% of patients switching from placebo to Copemyl. Anti-GA antibodies were tested throughout the whole duration of both core and extension study (Fig. [3](#Fig3){ref-type="fig"}). During the 9-month double blind study, the anti-GA-positive proportion of patients and antibody titer were similar in GA- and Copemyl-treated patients. Interestingly, when GA patients switched to Copemyl, their antibody titer remained equivalent to those of patients originally randomized to Copemyl. These findings allowed the authors to conclude that efficacy and safety of Copemyl are maintained over a certain time and that switching from GA to Copemyl might be done without loss of efficacy, safety, or tolerability.Fig. 2Mean number in Gd+ new and persisting lesions in patients enrolled in the open label extension trial of the GATE study \[[@CR32]\]. Groups are divided according to randomization in double blind GATE trial \[[@CR31]\].This figure is slightly modified in terms of color and with supplementary notes from \[[@CR32]\]. This work is licensed under the Creative Commons Attribution-NonCommercial 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc/3.0/> or send a letter to Creative Commons, P.O. Box 1866, Mountain View, CA 94042, USA Fig. 3Mean anti-GA antibody titers in subjects treated with GA or *n*-GA in the GATE study (months 0--9) \[[@CR31]\] and in the same groups of patients when treated with *n*-GA in open label extension of the trial (months 9--24) \[[@CR32]\].This figure is slightly modified in terms of color and with supplementary notes from \[[@CR32]\]. This work is licensed under the Creative Commons Attribution-NonCommercial 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc/3.0/> or send a letter to Creative Commons, P.O. Box 1866, Mountain View, CA 94042, USA

Discussion {#Sec6}
==========

Both the GATE study and its extension provide evidence in support of the equivalence between Copemyl and GA. In the GATE study, the equivalent margin (EM), which clearly is of pivotal importance in such studies, was decided taking into consideration the results of the pivotal studies of GA vs placebo. As previously described, the EM is defined as the largest difference between the originator and the test drug that can be judged as clinically acceptable, and should be no larger than differences observed in the superiority trial of the originator \[[@CR26]\]. Therefore, as in the Euro/Canadian trial in months 7--9 the mean number of Gd+ lesions in placebo-treated patients was 1.75 times higher than in GA-treated patients \[[@CR15]\], for the GATE trial the upper limit of the EM was set at 50% of that value, i.e., 1.375; consequently, the lower limit was set at 0.727, symmetrically in the log scale. The value of 50% was chosen because it is possible to estimate the expected effect on relapses from an observed effect on MRI lesions, according to the Sormani equation \[[@CR34], [@CR35]\]. An effect on MRI lesions as relative risk compared to the originator (RR) of 0.727 (reduction of 27.5%) translates into an effect on relapses as RR 0.825 (reduction of 17.5%); such a difference was considered non-clinically relevant. Furthermore, in equivalence trials it is crucial that an assay sensitivity is provided, as it quantifies to the ability of the trial to detect a difference between treatments, if such a difference exists \[[@CR36]\].

Authors of the GATE trial state that sample size calculation (with a dropout rate of 12% allowed) was performed to ensure a 98% power to demonstrate study sensitivity, a 92% power to show equivalence of GA and Copemyl, and a 90% power to show both sensitivity and equivalence. Results from the GATE trial were bolstered by the extension trial, in which MRI results are fully consistent with the hypothesis of the equivalence between Copemyl and GA. Furthermore, anti-GA antibodies monitoring throughout the whole duration of the open label and the extension trial provided interesting information. The incidence and titer of anti-GA were comparable with both forms of GA. Moreover, switching from GA to Copemyl did not affect anti-GA titers. These results demonstrate that GA and Copemyl have comparable immunogenicity, which is of great relevance when it comes to evaluating interchangeability of complex or biologic drugs \[[@CR37], [@CR38]\]. To our knowledge, this is the only new version of GA whose immunogenicity has been evaluated in MS patients.

Even with adequate EM and study sensitivity, and with immunological evidence in support, a few drawbacks of the GATE study need to be addressed: (1) the fact that the primary endpoint was not a clinical endpoint but an MRI surrogate of clinical activity, (2) the fact that over the observation period no differences in terms of ARR appeared in the three arms of the study.

The choice of the primary endpoint was de facto suggested by EMA, after the manufacturers of Copemyl on several occasions sought EMA scientific advice as regards the type of new data required \[[@CR22]\]. In fact, the EMA CHMP stated that MRI measures are acceptable to detect effect and establish equivalence of two products containing GA in a shorter study duration, in cases that the quality data indicate a high level of similarity \[[@CR22]\]. Also, the current CHMP guideline on multiple sclerosis \[[@CR39]\] declares MRI endpoints to be sufficient for demonstrating similarity of two products in the context of biosimilar and generic applications. Anyway, such endpoints could be perceived as puzzling, as to date MRI activity has not been the primary endpoint in any phase III trial in MS. However, over the last years there has been mounting evidence of a strong association between MRI activity and clinical activity. Two meta-analyses of studies encompassing several DMDs demonstrated that in MS relapse rate strongly correlates with Gd+ lesions, and, more importantly, that the magnitude of the effect of the drug on MRI parameters can predict the magnitude of the benefit in terms of ARR \[[@CR34], [@CR35]\]. As far as it concerns specifically GA, the correlations between MRI and clinical activity parameters are particularly robust, stronger than what was observed, for instance, in interferon-beta (IFN-β) studies. In fact, trials comparing GA and IFN-β head to head showed a similar efficacy on relapses, whereas the effect on MRI activity was somewhat less pronounced for GA \[[@CR40]--[@CR42]\] and meta-analysis confirmed these results \[[@CR43]\]. These observations were summarized in a paper published in*Nature Reviews Neurology* stating that for equivalence trials on a drug such as glatiramer acetate, with almost the same magnitude of effect on MRI activity and relapse rate, an MRI-based approach seems justified \[[@CR44]\].

In the GATE trial, the apparent lack of effect of both GA and Copemyl on relapse rate may result from multiple factors. The authors suggest that the trial was not designed or powered to show relapse rate reduction: the placebo group consisted only of 84 subjects and therefore the expected power to demonstrate an ARR reduction was less than 30%. In addition to that, the ARR of the placebo group was low, both at baseline (if compared to the US and the Euro-Canadian trial) and during the trial. This observation is not at all unexpected, as it is well known that ARR in the placebo groups of phase III trials in MS have consistently decreased over the years \[[@CR45]\]. It suggests that subjects included in the recent trials have less aggressive forms of MS than patients included in the early ones; thus, in order to detect an effect on ARR, larger sample trials are required in order to compensate for overall low event rates. Furthermore, the duration of the GATE trial was only 9 months. In fact, evidence from a trial with GA in 481 patients with a first demyelinating event (CIS) at high risk of developing MS \[[@CR46]\] suggests that the effect of GA on clinical activity emerges over placebo after at least 6 months of treatment, suggesting that a 9-month observation time might have played a role in not allowing an effect on relapses to emerge. Anyway, even taking these considerations into account, the lack of effect on relapses of both active compounds is somehow puzzling.

The results of the extension study confirmed the effect of Copemyl on MRI activity as patients previously treated with placebo showed a reduction of T1 Gd-enhancing lesions and T2 lesions at the end of the trial. The effect on MRI parameters was similar in the two cohorts of patients previously treated with Copemyl or GA: in other words, the effect on MRI was maintained in patients who switched from GA to Copemyl.

The rate of AEs in both GATE and its extension trials, namely injection site reaction and post-injection systemic reaction, was lower than that reported in the trial of GA in CIS mentioned above \[[@CR46]\] and, although it could probably have been underestimated, it was even in patients treated with Copemyl or GA.

Conclusions {#Sec7}
===========

Many medications are currently available for the treatment of MS, with the clear advantage of offering many options and the objective to tailor the therapy to patient characteristics and to provide higher efficacy for breakthrough disease. As a result, though, the costs of MS treatment have increased, as the prices of highly effective MS DMDs are generally higher than those of platform therapies. Efforts should be made to address this question, which potentially limits a wider access to some therapies. One probable reason for the skyrocketing costs of MS DMDs is that DMDs present on the market for decades have never faced price competition from lower-cost equivalent drugs \[[@CR47]\]. However, the effect of the availability of a generic DMD on the costs of MS therapy is still unclear, because it will heavily depend upon its price and the extent of its use, i.e., the extent of how neurologists and patients are confident that the new drug has comparable efficacy, safety, and tolerability as the brand drug. Clinicians will therefore ask to be reassured on the comparable safety and efficacy profile of new formulations. A debate is ongoing on these issues, in particular on two additional aspects: how definitions of regulatory guidelines are exhaustive, clear, indisputable \[[@CR48]\], and how new formulations are actually identical to the original medication, an aspect particularly important for NBCDs, and especially for glatiramoids \[[@CR18], [@CR49]\]. Glatiramoids are in fact immunomodulators, altering pathogenetic immune mechanisms, but also implying possible risks such as immunotoxicity, induction of autoimmune disorders, and lack of efficacy \[[@CR50]\]. As glatiramoids are not amenable to conventional methods of demonstrating bioequivalence, according to the same author \[[@CR50]\], the only way to test their safety and efficacy is to produce robust data from clinical trials. The evidence presented in this review should reinforce the confidence of clinicians as far as it concerns Copemyl, as published data in fact suggest equivalence of Copemyl and GA on the basis of immunological and MRI outcomes, thus making Copemyl a viable option, along with interferons or teriflunomide among others, for patients suffering with mild to moderate forms of MS. Anyway, the drawbacks pertaining to clinical data should be taken into account, and there is a need for post-marketing evidence comparing the two compounds in everyday practice and further confirming their equivalence.
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